Second-Guessing FDA? Sage Zulresso Denied Add-On Status In Medicare
Executive Summary
Medicare’s doubts about trial design for Sage’s postpartum depression therapy suggests even ‘breakthrough’-designated products can struggle with the ‘substantial clinical improvement’ standard for NTAP status. Denial of enhanced payment for Zulresso ends a long winning streak by innovators.
You may also be interested in...
Medicare Part B Shift To Discourage Prescribing Of Costly New 340 Drugs Weighed By MedPAC
Linking clinical superiority to payments is another recommendations on Medicare reimbursement for separately payable drugs in the hospital outpatient prospective payment system under consideration by the Medicare Payment Advisory Commission.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.